

# Mika Naganawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4506196/publications.pdf>

Version: 2024-02-01

114  
papers

3,583  
citations

136950

32  
h-index

161849

54  
g-index

119  
all docs

119  
docs citations

119  
times ranked

3235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. <i>JAMA Neurology</i> , 2018, 75, 1215.	9.0	304
2	Lower synaptic density is associated with depression severity and network alterations. <i>Nature Communications</i> , 2019, 10, 1529.	12.8	277
3	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. <i>Alzheimer's and Dementia</i> , 2020, 16, 974-982.	0.8	170
4	PET kinetic analysisâ€”compartmental model. <i>Annals of Nuclear Medicine</i> , 2006, 20, 583-588.	2.2	164
5	High Occupancy of Sigma-1 Receptors in the Human Brain after Single Oral Administration of Fluvoxamine: A Positron Emission Tomography Study Using [ <sup>11</sup> C]SA4503. <i>Biological Psychiatry</i> , 2007, 62, 878-883.	1.3	122
6	Adenosine A2A Receptors Measured with [ <sup>11</sup> C]TMSX PET in the Striata of Parkinson's Disease Patients. <i>PLoS ONE</i> , 2011, 6, e17338.	2.5	122
7	Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. <i>Annals of Neurology</i> , 2020, 87, 329-338.	5.3	112
8	Extraction of a Plasma Time-Activity Curve From Dynamic Brain PET Images Based on Independent Component Analysis. <i>IEEE Transactions on Biomedical Engineering</i> , 2005, 52, 201-210.	4.2	107
9	Assessment of a white matter reference region for <sup>11</sup> C-UCB-J PET quantification. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1890-1901.	4.3	77
10	Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. <i>NeuroImage</i> , 2014, 86, 164-171.	4.2	75
11	Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [ <sup>11</sup> C]TMSX PET. <i>Synapse</i> , 2007, 61, 778-784.	1.2	67
12	Association of In Vivo $\mu$ -Opioid Receptor Availability and the Transdiagnostic Dimensional Expression of Trauma-Related Psychopathology. <i>JAMA Psychiatry</i> , 2014, 71, 1262.	11.0	67
13	First-in-Human Evaluation of <sup>18</sup> F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. <i>Journal of Nuclear Medicine</i> , 2021, 62, 561-567.	5.0	60
14	In Vivo Synaptic Density Imaging with <sup>11</sup> C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1780-1786.	5.0	57
15	Mapping of human cerebral sigma1 receptors using positron emission tomography and [ <sup>11</sup> C]SA4503. <i>NeuroImage</i> , 2007, 35, 1-8.	4.2	56
16	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [ <sup>11</sup> C]UCB-J. <i>Alzheimer's and Dementia</i> , 2022, 18, 2527-2536.	0.8	55
17	Evaluation of the agonist PET radioligand [ <sup>11</sup> C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, testâ€”retest reproducibility and receptor occupancy by the antagonist PF-04455242. <i>NeuroImage</i> , 2014, 99, 69-79.	4.2	54
18	Association of A $\beta$ <sup>2</sup> deposition and regional synaptic density in early Alzheimerâ€™s disease: a PET imaging study with [ <sup>11</sup> C]UCB-J. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.	6.2	53

#	ARTICLE	IF	CITATIONS
19	Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [ <sup>11</sup> C]UCBâ€Ž positron emission tomography study. <i>Epilepsia</i> , 2020, 61, 2183-2193.	5.1	51
20	In vivo evidence of lower synaptic vesicle density in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 7690-7698.	7.9	51
21	Receptor Occupancy of the $\mu$ -Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer <sup>11</sup> C-LY2795050. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 260-266.	2.5	47
22	A singleâ€Žcenter, openâ€Žlabel positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. <i>Epilepsia</i> , 2019, 60, 958-967.	5.1	45
23	Assessment of population-based input functions for Patlak imaging of whole body dynamic <sup>18</sup> F-FDG PET. <i>EJNMMI Physics</i> , 2020, 7, 67.	2.7	45
24	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. <i>Biological Psychiatry</i> , 2018, 84, 413-421.	1.3	43
25	Parametric Imaging With PET and SPECT. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 1-23.	3.7	43
26	Comparison of [ <sup>11</sup> C]UCB-J and [ <sup>18</sup> F]FDG PET in Alzheimerâ€™s disease: A tracer kinetic modeling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2395-2409.	4.3	43
27	Kinetic Modeling of <sup>11</sup> C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1818-1825.	4.3	42
28	PET kinetic analysis â€ŽPitfalls and a solution for the Logan plot. <i>Annals of Nuclear Medicine</i> , 2007, 21, 1-8.	2.2	39
29	Event-by-Event Continuous Respiratory Motion Correction for Dynamic PET Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1084-1090.	5.0	39
30	Testâ€ŽRetest Reproducibility of Binding Parameters in Humans with <sup>11</sup> C-LY2795050, an Antagonist PET Radiotracer for the $\mu$ Opioid Receptor. <i>Journal of Nuclear Medicine</i> , 2015, 56, 243-248.	5.0	35
31	First-in-Human Assessment of <sup>11</sup> C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 553-560.	5.0	35
32	A feasibility study of [ <sup>11</sup> C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma1 and dopamine D2-like receptors. <i>Annals of Nuclear Medicine</i> , 2006, 20, 569-573.	2.2	33
33	Data-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PET. <i>Physics in Medicine and Biology</i> , 2019, 64, 065002.	3.0	32
34	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.	7.9	32
35	Data-Driven Motion Detection and Event-by-Event Correction for Brain PET: Comparison with Vicra. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1397-1403.	5.0	32
36	PET kinetic analysis: wavelet denoising of dynamic PET data with application to parametric imaging. <i>Annals of Nuclear Medicine</i> , 2007, 21, 379-386.	2.2	31

#	ARTICLE	IF	CITATIONS
37	Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 679-687.	6.4	30
38	Omission of serial arterial blood sampling in neuroreceptor imaging with independent component analysis. <i>NeuroImage</i> , 2005, 26, 885-890.	4.2	29
39	Imaging of Synaptic Density in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 60S-67S.	5.0	29
40	PET kinetic analysis: error consideration of quantitative analysis in dynamic studies. <i>Annals of Nuclear Medicine</i> , 2008, 22, 1-11.	2.2	28
41	Imaging of I2-imidazoline receptors by small-animal PET using 2-(3-fluoro-[4-11C]tolyl)-4,5-dihydro-1H-imidazole ([11C]FTIMD). <i>Nuclear Medicine and Biology</i> , 2010, 37, 625-635.	0.6	28
42	Novel <sup>18</sup> F-Labeled $\mu$ -Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of <sup>18</sup> F-LY2459989 in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2018, 59, 140-146.	5.0	28
43	Event-by-event respiratory motion correction for PET with 3D internal-1D external motion correlation. <i>Medical Physics</i> , 2013, 40, 112507.	3.0	27
44	First-in-Human Assessment of the Novel PDE2A PET Radiotracer <sup>18</sup> F-PF-05270430. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1388-1395.	5.0	27
45	Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2021, 73, 1404-1411.	5.8	25
46	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 111, 44-53.	3.1	25
47	Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. <i>Molecular Psychiatry</i> , 2022, 27, 2273-2281.	7.9	25
48	Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes. <i>Molecular Imaging and Biology</i> , 2018, 20, 835-845.	2.6	24
49	Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1327-1338.	6.4	23
50	Evaluation of PET Brain Radioligands for Imaging Pancreatic $\beta$ -Cell Mass: Potential Utility of 11C-(+)-PHNO. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1249-1254.	5.0	22
51	Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. <i>Neuropsychopharmacology</i> , 2019, 44, 1714-1719.	5.4	22
52	Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy. <i>Bulletin of Mathematical Biology</i> , 2019, 81, 3508-3541.	1.9	21
53	Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18 F-FP-DTBZ in baboons. <i>Nuclear Medicine and Biology</i> , 2016, 43, 743-751.	0.6	20
54	Development and In Vivo Evaluation of a $\mu$ -Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1023-1030.	5.0	20

#	ARTICLE	IF	CITATIONS
55	Robust estimation of the arterial input function for Logan plots using an intersectional searching algorithm and clustering in positron emission tomography for neuroreceptor imaging. <i>NeuroImage</i> , 2008, 40, 26-34.	4.2	19
56	PET Imaging of Pancreatic Dopamine D <sub>2</sub> and D <sub>3</sub> Receptor Density with <sup>11</sup> C-(+)-PHNO in Type 1 Diabetes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 570-576.	5.0	19
57	Simplified Quantification of <sup>11</sup> C-UCB-J PET Evaluated in a Large Human Cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 418-421.	5.0	19
58	Differential effects of age on human striatal adenosine A <sub>1</sub> and A <sub>2A</sub> receptors. <i>Synapse</i> , 2012, 66, 832-839.	1.2	18
59	Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging. <i>Diabetologia</i> , 2018, 61, 2598-2607.	6.3	18
60	Distribution volume as an alternative to the binding potential for sigma1 receptor imaging. <i>Annals of Nuclear Medicine</i> , 2007, 21, 533-535.	2.2	17
61	Tracer Kinetic Modeling of [ <sup>11</sup> C]AFM, a New PET Imaging Agent for the Serotonin Transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1886-1896.	4.3	17
62	Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static <sup>18</sup> F-FDG PET as a function of injected dose. <i>Physics in Medicine and Biology</i> , 2018, 63, 175015.	3.0	17
63	Partial volume correction analysis for <sup>11</sup> C-UCB-J PET studies of Alzheimer's disease. <i>NeuroImage</i> , 2021, 238, 118248.	4.2	17
64	Generation of parametric $K_i$ images for FDG PET using two 5-min scans. <i>Medical Physics</i> , 2021, 48, 5219-5231.	3.0	16
65	Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory <sup>11</sup> C-UCB-J positron emission tomography study in humans. <i>Addiction Biology</i> , 2022, 27, e13123.	2.6	16
66	Wavelet denoising for voxel-based compartmental analysis of peripheral benzodiazepine receptors with 18F-FEDAA1106. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 416-423.	6.4	15
67	Atlas-Based Multiorgan Segmentation for Dynamic Abdominal PET. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 50-62.	3.7	14
68	Shortened protocol in practical [ <sup>11</sup> C]SA4503-PET studies for sigma1 receptor quantification. <i>Annals of Nuclear Medicine</i> , 2008, 22, 143-146.	2.2	13
69	Test-retest variability of adenosine A2A binding in the human brain with <sup>11</sup> C-TMSX and PET. <i>EJNMMI Research</i> , 2014, 4, 76.	2.5	13
70	Preclinical Evaluation of <sup>18</sup> F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1448-1453.	5.0	13
71	Generation of synthetic PET images of synaptic density and amyloid from <sup>18</sup> F-FDG images using deep learning. <i>Medical Physics</i> , 2021, 48, 5115-5129.	3.0	12
72	MAP-based kinetic analysis for voxel-by-voxel compartment model estimation: Detailed imaging of the cerebral glucose metabolism using FDG. <i>NeuroImage</i> , 2006, 29, 1203-1211.	4.2	11

#	ARTICLE	IF	CITATIONS
73	Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine. <i>Human Brain Mapping</i> , 2022, 43, 1419-1430.	3.6	11
74	Kinetic Modeling and Testâ€“Retest Reproducibility of <sup>11</sup> C-EKAP and <sup>11</sup> C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the Î²-Opioid Receptor in Humans. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1636-1642.	5.0	10
75	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
76	Novel Kappa Opioid Receptor Agonist as Improved PET Radiotracer: Development and in Vivo Evaluation. <i>Molecular Pharmaceutics</i> , 2019, 16, 1523-1531.	4.6	9
77	Improvement of likelihood estimation in Logan graphical analysis using maximum a posteriori for neuroreceptor PET imaging. <i>Annals of Nuclear Medicine</i> , 2009, 23, 163-171.	2.2	8
78	A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studies. <i>NeuroImage</i> , 2010, 49, 578-586.	4.2	8
79	Adaptive data-driven motion detection and optimized correction for brain PET. <i>NeuroImage</i> , 2022, 252, 119031.	4.2	8
80	Temporal and spatial blood information estimation using Bayesian ICA in dynamic cerebral positron emission tomography. , 2007, 17, 979-993.		7
81	Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer <sup>11</sup> C-TASP699. <i>Journal of Nuclear Medicine</i> , 2022, 63, 609-614.	5.0	7
82	Event-by-event respiratory motion correction for PET with 3-Dimensional internal-external motion correlation. , 2012, , .		5
83	PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. <i>Cerebral Cortex</i> , 2021, 31, 2787-2798.	2.9	5
84	Doctor-to-Patient communication by 2.5G mobile phone; preliminary study. <i>International Congress Series</i> , 2005, 1281, 196-199.	0.2	4
85	Comparative evaluation of two glycine transporter 1 radiotracers [ <sup>11</sup> C]GSK931145 and [ <sup>18</sup> F]MK-6577 in baboons. <i>Synapse</i> , 2016, 70, 112-120.	1.2	4
86	F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [ <sup>11</sup> C]UCB-J PET. <i>Biological Psychiatry</i> , 2018, 83, S296.	1.3	4
87	142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations. <i>Biological Psychiatry</i> , 2019, 85, S59.	1.3	4
88	Omission of serial arterial blood sampling for quantitative analysis of monkey PET data using independent component analysis-based method. , 2007, , .		3
89	Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, S145-S146.	1.2	3
90	ICAâ€“derived sources of synaptic density PET ([ <sup>11</sup> C]UCBâ€“) relate to cognitive impairment severity in Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041197.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044211.	0.8	2
92	Imaging detailed glucose metabolism in the brain using MAP estimation in Positron Emission Tomography. , 2005, 2005, 4477-9.		1
93	Practical Consideration about Cost Functions of Spatial Independent Component Analysis in Medical Image Processing. , 2005, 2005, 1120-2.		1
94	Whole Shape Measurement System Using a Single Camera and a Cylindrical Mirror. , 2006, , .		1
95	Parametric Imaging of the total volume of distribution using MAP estimation for logan graphical analysis. <i>NeuroImage</i> , 2008, 41, T83.	4.2	1
96	Brain tissue selection procedures for image derived input functions derived using independent components analysis. , 2012, 2012, 5987-90.		1
97	Quantification of Neuroreceptors and Neurotransporters. <i>NeuroMethods</i> , 2012, , 149-161.	0.3	1
98	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037791.	0.8	1
99	Validation of a simplified tissue-to-reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [11C]UCB-J PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e045928.	0.8	1
100	Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, S119-S120.	1.2	1
101	Formation of binding potential maps of adenosine A1 and A2A receptors using independent component analysis without arterial blood sampling. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S606-S606.	4.3	1
102	Three-Dimensional Measurement System Using a Cylindrical Mirror. <i>Lecture Notes in Computer Science</i> , 2005, , 399-408.	1.3	1
103	Clustering approach for voxel-based Logan plot to improve noise reduction capability. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S632-S632.	4.3	1
104	3D Imaging System for Visualizing and Monitoring Patients. , 2005, 2005, 3735-7.		0
105	Reduction of noise-induced underestimation in Logan graphical analysis using scale invariant linear estimation. <i>NeuroImage</i> , 2008, 41, T82.	4.2	0
106	P265: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P832.	0.8	0
107	ICP183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P152.	0.8	0
108	S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGING. <i>Schizophrenia Bulletin</i> , 2019, 45, S310-S311.	4.3	0

#	ARTICLE	IF	CITATIONS
109	P4â€481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's and Dementia, 2019, 15, P1497.	0.8	0
110	ICâ€Pâ€140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTITRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.	0.8	0
111	Association between cerebral amyloid accumulation and synaptic density in Alzheimer's disease: A multitracers PET study. Alzheimer's and Dementia, 2020, 16, e043631.	0.8	0
112	ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY. American Journal of Geriatric Psychiatry, 2020, 28, S123-S124.	1.2	0
113	Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease. American Journal of Geriatric Psychiatry, 2021, 29, S47-S48.	1.2	0
114	Imaging the Effect of Ketamine on Synaptic (SV2A) Density. Biological Psychiatry, 2021, 89, S35.	1.3	0